Brokers Set Expectations for MBX Biosciences Q1 Earnings

Key Points

• Lifesci Capital started coverage of MBX Biosciences’ upcoming Q1 2027 results with an estimate of losses of $0.74 per share, while keeping a Strong-Buy rating on the stock.
• The firm also projected continued quarterly losses for the rest of 2027, with EPS estimates of -$0.77 in Q2, -$0.80 in Q3, and -$0.85 in Q4.
• Analyst sentiment remains generally positive overall: MBX has a Moderate Buy consensus rating and an average price target of $53.25, while the stock recently traded near $40.97.

MBX Biosciences, Inc. (NASDAQ:MBX - Free Report) - Equities research analysts at Lifesci Capital issued their Q1 2027 earnings estimates for shares of MBX Biosciences in a note issued to investors on Thursday, May 7th. Lifesci Capital analyst P. Dolezal expects that the company will post earnings of ($0.74) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for MBX Biosciences' current full-year earnings is ($2.90) per share. Lifesci Capital also issued estimates for MBX Biosciences' Q2 2027 earnings at ($0.77) EPS, Q3 2027 earnings at ($0.80) EPS and Q4 2027 earnings at ($0.85) EPS.

MBX has been the subject of a number of other research reports. TD Cowen restated a "buy" rating on shares of MBX Biosciences in a report on Thursday, March 12th. Truist Financial set a $50.00 price objective on shares of MBX Biosciences in a research report on Monday, March 9th. Wall Street Zen upgraded shares of MBX Biosciences from a "sell" rating to a "hold" rating in a report on Saturday. Barclays initiated coverage on shares of MBX Biosciences in a research report on Tuesday, January 27th. They issued an "overweight" rating and a $66.00 price objective on the stock. Finally, Guggenheim boosted their price objective on shares of MBX Biosciences from $77.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $53.25.

MBX Biosciences Stock Performance

Shares of NASDAQ MBX opened at $40.97 on Monday. The stock has a market cap of $1.95 billion, a P/E ratio of -18.54 and a beta of 0.78. The firm has a 50 day moving average price of $30.98 and a 200 day moving average price of $31.04. MBX Biosciences has a 52-week low of $9.43 and a 52-week high of $44.89.

MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.15.

Insider Activity at MBX Biosciences

In other MBX Biosciences news, CEO P. Kent Hawryluk acquired 18,500 shares of the business's stock in a transaction dated Friday, March 13th. The shares were acquired at an average price of $28.41 per share, with a total value of $525,585.00. Following the completion of the transaction, the chief executive officer directly owned 486,777 shares in the company, valued at $13,829,334.57. This trade represents a 3.95% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Institutional Trading of MBX Biosciences

A number of institutional investors have recently made changes to their positions in MBX. Russell Investments Group Ltd. raised its position in MBX Biosciences by 4,131.4% during the third quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company's stock worth $26,000 after acquiring an additional 1,446 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in MBX Biosciences during the third quarter worth $27,000. GF Fund Management CO. LTD. bought a new stake in MBX Biosciences during the fourth quarter worth $28,000. Strs Ohio raised its position in MBX Biosciences by 128.6% during the first quarter. Strs Ohio now owns 1,600 shares of the company's stock worth $48,000 after acquiring an additional 900 shares in the last quarter. Finally, Royal Bank of Canada raised its position in MBX Biosciences by 59.6% during the fourth quarter. Royal Bank of Canada now owns 1,532 shares of the company's stock worth $49,000 after acquiring an additional 572 shares in the last quarter.

About MBX Biosciences

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.